Peripheral artery disease is a condition in which plaque, comprising of fat, calcium, cholesterol, fibrous tissue and other substances present in the blood, build-up in arteries that supply blood to the brain, limbs and other organs. Atherosclerosis is a condition when plaques build-up in the arteries and limits the oxygen-rich blood flow to the body. Peripheral artery disease affects the leg arteries that can cause numbness and pain. In severe cases, gangrene (tissue death) can occur that can further lead to leg amputation. Bayer AG is in the process of developing rivaroxaban as a factor IXa inhibitors for the treatment of peripheral artery disease. Proteon Therapeutics, Inc. is in the process of developing vonapanitase as an extracellular matrix protein modulator for the treatment of the disease. Some of the companies having a pipeline of peripheral artery disease include Bayer AG, Proteon Therapeutics Inc., Juventas Therapeutics, Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.